AMGN Amgen Inc. logo

AMGN Amgen Inc.

Healthcare
$339.30+0.56%ClosedMarket Cap: $183.12B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

24.54

PEG

0.28

P/B

19.94

P/S

4.92

EV/EBITDA

13.17

DCF Value

$1,001.58

FCF Yield

4.7%

Div Yield

2.9%

Margins & Returns

Gross Margin

71.5%

Operating Margin

31.6%

Net Margin

20.9%

ROE

89.4%

ROA

8.4%

ROIC

13.9%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$8.62B$1.82B$
Q4 null$9.90B$1.33B$
FY null$36.74B$7.71B$
Q3 null$9.56B$3.22B$

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$352.00

Target (Median)

$357.50

Target Range

$185.00 - $427.00

4 Strong Buy10 Buy19 Hold2 Sell1 Strong Sell
Piper SandlerOverweight
2026-05-14
GuggenheimNeutral
2026-05-04
Truist SecuritiesHold
2026-05-01
UBSBuy
2026-04-13
Morgan StanleyEqual Weight
2026-04-10

Trading Activity

Insider Trades

View All
MILES AMY Edirector
SellThu May 21
Kullman Ellen Jamisondirector
SellThu May 21
Klotman Mary E.director
SellThu May 21
Jacks Tylerdirector
SellThu May 21
ISHRAK OMARdirector
SellThu May 21

Congress Trades

View All
Maria Elvira SalazarSell
Mon May 11
Mark WarnerSell
Fri May 01
Maria Elvira SalazarBuy
Wed Apr 22

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - General

Country

US

Exchange

Beta

0.43

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Peers